Effect of Intranasal Mupirocin on Rate of Staphylococcus Aureus Surgical Site Infection Following Cesarean Sections

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified June 2010 by Hillel Yaffe Medical Center
Sponsor:
Information provided by:
Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:
NCT01152593
First received: May 31, 2010
Last updated: June 28, 2010
Last verified: June 2010
  Purpose

The investigators believe that irradication of nose colonization of staphyloccocus aureus will reduce the incidence of surgical site infections after cesarean section.


Condition Intervention
Surgical Wound Infection
Cesarean Section
Staphylococcus Aureus
Drug: Mupirocin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by Hillel Yaffe Medical Center:

Primary Outcome Measures:
  • Reduction of the incidence of surgical site infections after cesarean section [ Time Frame: Four years ] [ Designated as safety issue: No ]

Estimated Enrollment: 400
Study Start Date: July 2010
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intranasal Mupirocin Drug: Mupirocin
Intranasal cream given to patient after confirmation of colonization

  Eligibility

Genders Eligible for Study:   Female
Criteria

Inclusion Criteria:

  • Women assigned to undergo cesarean section

Exclusion Criteria:

  • All others
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01152593

Locations
Israel
Hillel Yaffe Medical Center Not yet recruiting
Hadera, Israel, 38100
Contact: Gai Shrem, MD       gais@hy.health.gov.il   
Principal Investigator: Gai Shrem, MD         
Sponsors and Collaborators
Hillel Yaffe Medical Center
  More Information

No publications provided

Responsible Party: Gai Shrem, MD, Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT01152593     History of Changes
Other Study ID Numbers: HYMC0033-10
Study First Received: May 31, 2010
Last Updated: June 28, 2010
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Surgical Wound Infection
Wound Infection
Infection
Postoperative Complications
Pathologic Processes
Wounds and Injuries
Mupirocin
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 18, 2014